Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 百利药业是一家聚焦于全球生物医药前沿领域，立足于解决临床未被满足的需求，具备包括小分子化学药、大分子生物药及ADC药物的全系列药品研究开发能力，并拥有从中间体、原料药到制剂一体化优势的、覆盖“研发—生产—营销”完整全生命周期商业化运营能力的生物医药企业。 公司旗下拥有2个新药研发中心（西雅图免疫、百利多特生物）、1个抗体及ADC药物生产企业，1个化学中间体生产企业及1个化学原料药生产企业，2个化学药制剂生产企业、2个营销公司。
Main Business 药品研发、生产与营销一体化。
Legal Representative 朱义
Top Executives
董事长：朱义
董事：朱海,卓识,康健,张苏娅,DAVID GUOWEI WANG
独立董事：李明远,杨敏,俞雄,肖耿
Top 5 Shareholder
Shareholder name Nature Holding Date
朱义限售股74.35%30/09/2024
OAP III(HK)Limited流通A股7.11%30/09/2024
张苏娅限售股2.39%30/09/2024
招商银行股份有限公司－华夏上证科创板50成份交易型开放式指数证券投资基金流通A股1.54%30/09/2024
中国工商银行股份有限公司－易方达上证科创板50成份交易型开放式指数证券投资基金流通A股0.95%30/09/2024
Company Secretary 陈英格
Solicitors 北京市君合律师事务所
Auditors 立信会计师事务所（特殊普通合伙）
Tel No 028-85321013
Fax No 028-85320270
Website www.baili-pharm.com
Email ir@baili-pharm.com
Company Address
Register: 四川省成都市温江区成都海峡两岸科技产业园百利路161号一幢一号
Office: 四川省成都市温江区成都海峡两岸科技产业园百利路161号一幢一号;成都市高新区高新国际广场B座10楼
Listing Date 06/01/2023
Shares Capital
Shares Capital: 401,000,000
Total A Share: 401,000,000
Listed A Share: 90,450,990
Non-tradable A Share: 310,549,010
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ -1.950
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 0.379
Market Capitalization(RMB) 17.667B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.